ChineseInvestors.com, Inc. (CIIX) Pursues Continued Success in CBD Markets

ChineseInvestors.com, Inc. (CIIX) Pursues Continued Success in CBD Markets
ChineseInvestors.com, Inc. (CIIX) Pursues Continued Success in CBD Markets
by is licensed under

Leveraging its achievements of amassing a 100,000+ user base, establishing a recognizable 18-year-old brand, and sharpening its focus on a market that exceeds two billion Chinese-speaking individuals, ChineseInvestors.com (OTCQB: CIIX) has reached a first-in-the-marketplace milestone by launching the world’s first and only Chinese language, cannabinoid-based therapeutic health products web store, http://www.ChineseCBDoil.com. After making a successful investment in the marijuana market, the company recently expanded into the retail and online sale of cannabidiol (CBD), which has become one of the fastest-growing market categories in the United States. “With an annual growth rate of nearly 60 percent, CBD oil has become one of the fastest growing market categories in the country, and U.S.-based ChineseInvestors.com aims to capitalize on this meteoric growth by marketing holistic CBD-based products to the more than two billion Chinese speaking people in the world. CBD oil is considered to have a broad range of medical benefits, and it is non-psychoactive with low-THC and high-CBD content. CBD has shown varying degrees of efficacy in treating epilepsy, Alzheimer’s disease, cirrhosis, pain, anxiety and stress. Given the wide ranging practice of holistic-based Eastern medicine, acceptance and use of CBD oils is not only a natural adjunct, but also an enormous potential revenue generator for ChineseInvestors.com, which suggests that online sales and future retail outlets could easily exceed expectations.”

Read the full article

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer 


Tags
Cannabis Focus, Cannabis Industry, Health
Thumbnail Photo Credit: by is licensed under